Compare TMDX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | APGE |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 2019 | 2023 |
| Metric | TMDX | APGE |
|---|---|---|
| Price | $99.21 | $77.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $154.00 | $109.25 |
| AVG Volume (30 Days) | 923.9K | ★ 1.0M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | N/A |
| EPS | ★ 4.87 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $18.73 | N/A |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $62.42 | $26.20 |
| 52 Week High | $156.00 | $85.04 |
| Indicator | TMDX | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 24.72 | 60.14 |
| Support Level | N/A | $73.06 |
| Resistance Level | $131.86 | $81.04 |
| Average True Range (ATR) | 5.48 | 4.62 |
| MACD | -2.58 | 0.96 |
| Stochastic Oscillator | 3.82 | 73.26 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.